Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226

AIMS: In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)‐positive metastatic breast cancer. Here we report a pharmacokinetic subset analysis investigating a possible drug interaction between anastrozo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Clin Pharmacol
Autori principali: Hertz, Daniel L., Barlow, William E., Kidwell, Kelley M., Albain, Kathy S., Vandenberg, Ted A., Dakhil, Shaker R., Tirumali, Nagendra R., Livingston, Robert B., Gralow, Julie, Hayes, Daniel F., Hortobagyi, Gabriel N., Mehta, Rita S., Rae, James M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Drug Interactions
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876171/
https://ncbi.nlm.nih.gov/pubmed/26859101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12904
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi